SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who started this subject10/9/2001 9:44:31 PM
From: Harold Engstrom  Read Replies (1) of 10280
 
From Aventis Aug 2 PR:"Allegra®/Telfast® (fexofenadine) generated a 53.6% increase in half-year sales activity to euro 844 million (+ 60.7% on a reported basis), while second-quarter sales activity grew 43.4% to euro 460 million (+50.2% on a reported basis). In the United States, sales activity rose 37.5% to euro 680 million in the first half (+47% on a reported basis). Allegra® was a main growth driver in the United States, benefiting mainly from positive prescription trends. In Japan, the world's second-largest allergy market after the United States, sales of Allegra® have also been very strong since the product's launch in November 2000, rising to euro 82 million during the first six months of 2001."

This may have been posted here before, but I don't remember seeing it. Good growth in Allegra sales in Japan. Should be some flow through to Sepracor starting last quarter.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News